Abstract 128P
Background
Rectal cancer (RC) is a significant health concern, ranking as a prevalent form of colorectal cancer, which is third most common cancer diagnosed in both men and women in the United States. The estimations for 2023 project 106,970 new cases of colon cancer and 46,050 new cases of RC, highlighting the urgency to develop potential therapies for RC. Here, a network-based drug repurposing strategy was devised to identify drugs with the potential for repurposing as immune checkpoint inhibitors specifically for RC.
Methods
The study involved constructing a network of RC-associated immune checkpoint proteins (ICPs) and their induced protein interactions (P-ICP). Through network analysis, key target genes closely interacting with ICPs were identified. This was followed by network proximity analysis in the drug-target interaction (DTI) network and pathway cross-examination to identify potential immune checkpoint inhibitors among 109 distinct pathways associated with approved drugs.
Results
The developed approach successfully predicted 19 FDA-approved drugs with potential to target RC-associated ICP-induced pathways. Notably, three of these drugs including Bevacizumab, Cetuximab, and Capecitabine have already been utilized in RC treatment, validating the effectiveness of the strategy. Furthermore, six of the predicted drugs possess immunomodulatory properties, highlighting their potential in immune-related therapeutic applications. The analysis categorized the predicted pathways into two distinct groups: 13 immune pathways and 88 metabolic pathways, indicating the drugs' versatility in targeting different aspects of RC.
Conclusions
The network-based drug repurposing strategy presented in this study offers new opportunities for the rapid repurposing of FDA-approved medications in clinical trials for EC treatment. The identification of 19 drugs with potential immune checkpoint inhibitor properties and insight into useful drug combinations through drug-drug correlation analysis provide valuable contributions to the search for effective therapies against RC. These findings pave the way for further investigations and expedited development of potential treatments for this prevalent cancer type.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Research Foundation (NRF), Korea, under project BK21 FOUR.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract